Peking University Cancer Hospital & Institute: Rectal Neoplasms trials

The registry lists 17 Rectal Neoplasms studies with Peking University Cancer Hospital & Institute as lead sponsor. 9 are open to participants now and 0 have results posted.

Phase 2 7Phase 3 2No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Local Methylene Blue Injection for Prevention of Anastomotic Leakage and Permanent Stoma After Low Anterior Resection for Rectal CancerRecruitingNCT07833319Phase 2
• Comparison of [68Ga]Ga-CTR-FAPI and 18F-FDG PET/MRI for Lymph Node Staging in Rectal CancerNot yet recruitingNCT07552207Not applicable
• Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal CancerNot yet recruitingNCT07394192Phase 2
• Autologous Probiotics in Patients With Defunctioning Ileostomy Following LAR for Rectal CancerNot yet recruitingNCT07366047Not applicable
• Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer.RecruitingNCT06894797Not applicable
• The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal CancerNot yet recruitingNCT06609434Not applicable
• Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal CancerNot yet recruitingNCT06443671Phase 2/3
• Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)RecruitingNCT06229041Phase 3
• Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal CancerRecruitingNCT06209099Not applicable
• Study on the Applicability of CCR Criteria in Rectal CancerCompletedNCT06794099
• Establishment of MRI Model for pTRG in Rectal Cancer With Establishment ofActive, not recruitingNCT05374044
• The Role of TCM on ERAS of Rectal Cancer PatientsStatus unknownNCT04749381Phase 2
• Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal CancerStatus unknownNCT04405206
• Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on NeoantigenStatus unknownNCT04340401Phase 2
• Induction Chemotherapy for MRF-negative, Moderate-risk, Resectable Middle and Low Rectal CancerStatus unknownNCT04296240Phase 2
• Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal CancerCompletedNCT02864849Phase 2
• Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant TreatmentCompletedNCT02860234